After 24 weeks of treatment with either placebo, Pegozafermin 15 mg weekly, Pegozafermin 30 mg weekly, or Pegozafermin 44 mg every two weeks, the proportions of patients achieving fibrosis improvement were 7%, 22%, 26%, and 27%, respectively
Also, Novo Nordisk, the manufacturer of FDA-approved semaglutide products, has reported cases of impurities found in compounded semaglutidewith one specific product tested found to have over 24% impurities
Additionally, the NICE (National Institute for Health and Care Excellence) provides the clinical frameworks that pharmacies like ours follow to ensure medications are prescribed appropriately
Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome